← 返回

慢性淋巴细胞白血病患者白血病细胞暴露于冷物理血浆和血浆处理培养基后 ITGB 3 表达增加

英文原题:Increased Expression of ITGB 3 in CLL Patient leukemia Cells by Exposure to Cold Physical Plasma and Plasma-treated Medium.

查看英文原题

Increased Expression of ITGB 3 in CLL Patient leukemia Cells by Exposure to Cold Physical Plasma and Plasma-treated Medium.

PubMed 2024/01/01(内容时间) Int J Mol Cell Med Q3 · IF 1.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

慢性淋巴细胞白血病(CLL)是最常见的血液系统恶性肿瘤,有多种医学干预手段。近十年来,冷物理等离子体已成为未来癌症治疗中一种引人关注的制剂。

本研究旨在探究冷物理等离子体或冷物理等离子体处理液(PTL)是否影响CLL患者血细胞中整合素β3(ITGB3)的表达,ITGB3被假设介导癌症干细胞与骨髓微环境之间的相互作用。研究评估了这些处理对代谢活性、细胞死亡模式、脂质氧化及ITGB3基因表达的影响。直接冷物理等离子体和PTL暴露均增强了CLL患者细胞的脂质过氧化,但在健康参与者中程度较低。

此外,在冷物理等离子体或PTL暴露48h后,CLL患者白细胞的代谢活性优先降低。此外,与未处理组和健康对照组相比,冷物理等离子体和PTL处理提高了CLL患者白细胞中ITGB3 mRNA的表达。

总体而言,我们的研究表明直接冷物理等离子体和PTL暴露对白血病患者血液白细胞具有选择性效应,但需要进一步更详细的研究,为此类治疗方案作为未来疗法提供更多依据。

展开英文摘要原文

Chronic lymphocytic leukemia (CLL) is the most prevalent hematological cancer, with various medical interventions. In the recent decade, cold physical plasma has become an interesting agent for future cancer therapy. The goal of this study was to see whether cold physical plasma or cold physical plasma-treated liquid (PTL) affected integrin beta 3 (ITGB3) expression, which is hypothesized to mediate an interaction between cancer stem cells and the bone marrow microenvironment, in CLL patients' blood cells.

The metabolic activity, cell death pattern, lipid oxidation and ITGB3 gene expression of these treatments was evaluated. Both direct cold physical plasma and PTL exposure enhanced lipid peroxidation in cells of CLL patients, but to a lesser extent in healthy participants.

Furthermore, following 48h of cold physical plasma or PTL exposure, the metabolic activity of leukocytes was preferentially reduced in CLL patient leukocytes.

In addition, cold physical plasma and PTL treatment elevated ITGB3 mRNA expression in CLL patients' leukocytes compared to untreated and healthy controls. Collectively, our study suggests selective effects of direct cold physical plasma and PTL exposure on blood leukocytes from leukemia patients, but further and more detailed studies are needed to provide additional rationales for such treatment options as future therapy.

论文信息

作者
Golpour M、Sohbatzadeh F、Alimohammadi M、Yazdani Z、Fattahi S、Zaboli E、Rafiei A、Bekeschus S
第一作者单位
Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.Iran
通讯作者单位
ZIK Plasmatis, Leibniz Institute for Plasma Science and Technology (INP), Felix-Hausdorff-Str. 2, 17489 Greifswald, Germany.Germany
期刊
International journal of molecular and cellular medicine2024
原文标识
PubMed 39493511 · DOI 10.22088/IJMCM.BUMS.13.3.248